Mitomycin - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The mitomycin market size was valued at USD 198.33 million in 2025 and is estimated to grow from USD 214.59 million in 2026 to reach USD 318.24 million by 2031, at a CAGR of 8.20% during the forecast period (2026-2031). This report is segmented by Product Type (Mitomycin C Injection, Intravesical Solution, Pyelocalyceal Solution, Ophthalmic Kits), Therapeutic Area (Oncology, Urology, Ophthalmology, Others), End User (Hospitals, Cancer Centers, Ambulatory Surgery Centers, Others), Dosage Form (Intravenous, Intravesicles, and More), and Geography (North America, Europe, and More). Forecasts are Provided in Terms of Value (USD).

Global Mitomycin Market Trends and Insights

Rising Incidence of Non-Muscle-Invasive Bladder Cancer

Non-muscle-invasive bladder cancer accounted for 80% of the estimated 84,530 new bladder cancer cases in the United States in 2026. Globally, bladder cancer recorded 614,000 new cases in 2024.

Population aging and growth have increased the number of patients requiring diagnosis, monitoring, and repeat treatment, with the disease burden remaining significant in North America and East Asia and case growth emerging in India and parts of Africa. Recurrence after transurethral resection remains a key driver of repeat intravesical treatment demand, with up to 70% of patients experiencing at least one recurrence, supporting recurring demand for mitomycin-based products in the mitomycin market.

Expansion of Sustained-Release Intravesical Formulations

UroGen Pharma’s RTGel platform has expanded the treatment role of mitomycin by extending drug contact with the urothelium. Conventional intravesical mitomycin C remains in the bladder for one to two hours, while the reverse-thermal hydrogel becomes a semi-solid gel at body temperature, enabling outpatient chemoablation without general anesthesia for eligible patients. ZUSDURI achieved a 78% complete response rate at three months in the Phase 3 ENVISION trial, and 64.5% of responders maintained a response at 36 months, with a median follow-up of 35.5 months. UGN-103 achieved a 77.8% complete response rate at three months, and a 94.5% six-month duration of response in the Phase 3 UTOPIA study, and UroGen submitted its NDA on August 17, 2026, creating opportunities for the mitomycin market to compete on treatment convenience and clinical durability.

Cytotoxic-Handling and Occupational-Safety Requirements

Mitomycin C is handled as a hazardous drug and requires dedicated preparation processes, trained pharmacy staff, and protective controls. These requirements increase operational complexity and costs for hospitals, ambulatory surgery centers, and community oncology practices, particularly smaller sites with limited compounding capacity and specialized staff. RTGel-based formulations require temperature-controlled reconstitution before administration, while UroGen designed UGN-103 with simplified reconstitution to reduce this burden. Narrow treatment windows and formulation-specific administration requirements can slow adoption in community settings and lower-resource health systems.

Other drivers and restraints analyzed in the detailed report include:

• Increasing Use of Mitomycin in Ophthalmic Antifibrotic Surgery
• Formulation-Specific Supply Resilience as a Procurement Priority
• Competition from BCG, Gemcitabine, and Combination Intravesical Therapies

Segment Analysis

Mitomycin C for Injection held 54.56% of the mitomycin market share in 2025. Its established use in systemic protocols for gastric, pancreatic, and anal cancers, as well as intravesical treatment for non-muscle-invasive bladder cancer, supports hospital demand. Accord Healthcare, Fresenius Kabi, Meitheal Pharmaceuticals, and Asian manufacturers compete in this category, where procurement decisions depend on pricing, manufacturing reliability, and API availability. Mitomycin for Pyelocalyceal Solution and Ophthalmic Mitomycin Kits represented smaller but established revenue pools. JELMYTO benefits from expanding real-world evidence and reimbursement access in the United States. A January 2025 multicenter analysis of 56 initial complete responders across 15 academic and community centers reported 68% recurrence-free survival at 3 years.

Mitomycin for Intravesical Solution is forecast to grow at a 9.45% CAGR through 2031. ZUSDURI generated USD 50.4 million in Q2 2026 revenue, while UroGen activated 1,444 sites of care and recorded 452 unique prescribers by June 30, 2026. UroGen submitted an NDA for UGN-103 on August 17, 2026. The next-generation product has simplified reconstitution and an extended shelf life, improving its practicality beyond specialist urology centers. Ophthalmic kits retain a stable role as minimally invasive glaucoma surgery expands mitomycin use for subconjunctival implant augmentation. The product mix is shifting toward high-volume generics, facing pricing pressure, and specialty formulations with higher value contribution.

Oncology accounted for 55.45% of the mitomycin market size in 2025. Mitomycin C is used in combination regimens for gastric and pancreatic adenocarcinoma, anal canal cancer, and HIPEC for peritoneal carcinomatosis. Its use across multiple treatment settings supports demand for conventional products and reduces reliance on a single oncology protocol. Hospital oncology pharmacies maintain established workflows for injectable preparation and administration. Ophthalmology and other surgical applications account for the remaining therapeutic demand, with trabeculectomy-associated use established across multiple geographies. A 2025 study reported 65.9% combined or qualified success at 8 years for trabeculectomy with mitomycin C in primary and secondary glaucoma.

Urology is forecast to grow at a 10.52% CAGR through 2031. Growth is supported by rising non-muscle-invasive bladder cancer incidence, chemoablative treatment options, and expanding commercial infrastructure for sustained-release products. The September 2026 AUA and Society of Urologic Oncology amendment included 40 new recommendations based on a literature review through December 2025. The guidance supports active surveillance, office-based treatment, and chemoablative therapies as alternatives to repeat transurethral resection for selected patients with recurrent low-grade disease. JELMYTO also supports kidney-sparing care for low-grade upper-tract urothelial carcinoma. This need is particularly relevant for older patients, whose median diagnosis age was 73 years in the source material.

Complete Report Scope:

• By Product Type
  • Mitomycin C for Injection
  • Mitomycin for Intravesical Solution
  • Mitomycin for Pyelocalyceal Solution
  • Ophthalmic Mitomycin Kits
• By Therapeutic Area
  • Oncology
  • Urology
  • Ophthalmology
  • Other Surgical Applications
• By End User
  • Hospitals
  • Specialty Cancer Centers
  • Ambulatory Surgery Centers
  • Ophthalmology Clinics
  • Cancer Research Institutes
  • Others
• By Dosage Form
  • Intravenous
  • Intravesicles
  • Topical
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 41.95% of the mitomycin market share in 2025, supported by two FDA-approved specialty formulations, established oncology reimbursement, and high bladder cancer prevalence. The United States recorded a bladder cancer prevalence of 0.101% in 2021, with 31 states reporting prevalence above 0.1%. ZUSDURI had 1,444 activated sites of care and generated USD 50.4 million in Q2 2026 revenue, while JELMYTO generated USD 94 million in 2025 and has 2026 revenue guidance of USD 97-101 million. Canada and Mexico use hospital-based injectable protocols, while Brazil and Argentina rely on public oncology programs and registered supply chains.

Europe is the second-largest regional market in the analysis. Germany, France, the United Kingdom, and Italy are high-volume oncology hubs with established non-muscle-invasive bladder cancer and glaucoma surgery protocols. The 2026 EAU guideline update added treatment tables for BCG-unresponsive tumors and a section on de-intensification for low-grade recurrent disease, supporting greater consideration of intravesical treatment options. The United Kingdom hosts the 25-site HIVEC-HEAT Phase 3 trial, while Spain and other countries retain conventional mitomycin C in public hospital oncology and urology formularies.

Asia-Pacific is forecast to grow at a CAGR of 10.67% through 2031. India supports production and consumption, with Intas Pharmaceuticals manufacturing Mutamycin for Accord BioPharma. Japan, Australia, South Korea, and other regional countries support demand through organ-preserving care, glaucoma surgery, and generic oncology procurement, while the Middle East and Africa offer potential through GCC procurement and South African public oncology formularies.

List of Companies Covered in this Report:

• Accord Healthcare, Inc.
• AdvaCare
• Alkem Laboratories Limited
• Cipla
• Eugia US LLC
• Fresenius
• Hikma Pharmaceuticals
• Intas Pharmaceutical
• Lupin
• Meitheal Pharmaceuticals, Inc.
• Pfizer
• Sun Pharmaceuticals Industries
• Teva Pharmaceutical Industries
• UroGen Pharma Ltd.
• Zydus Lifesciences Limited

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support